SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 2,574.41 |
| Enterprise Value ($M) | 2,497.50 |
| Book Value ($M) | 79.20 |
| Book Value / Share | 0.85 |
| Price / Book | 32.51 |
| NCAV ($M) | 52.99 |
| NCAV / Share | 0.57 |
| Price / NCAV | 48.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.43 |
| Return on Assets (ROA) | -0.90 |
| Return on Equity (ROE) | -1.35 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.88 |
| Current Ratio | 3.88 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 152.93 |
| Assets | 179.13 |
| Liabilities | 99.94 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Orbimed Advisors Llc | 0.60 | -82.99 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 10.80 | -3.46 | |
| 13G/A | Redmile Group, LLC | 9.90 | 7.71 | |
| 13G/A | Fmr Llc | 13.26 | -2.01 | |
| 13G/A | Vanguard Group Inc | 5.04 | 0.00 | |
| 13D/A | Samsara BioCapital, L.P. | 8.30 | -14.23 | |
| 13G/A | Invus Global Management, LLC | 15.80 | ||
| 13G/A | ARCH Venture Fund VIII, L.P. | |||
| 13G/A | Polaris Venture Partners VI, L.P. | 3.70 | -35.41 | |
| 13G/A | Artal International S.C.A. | 17.40 | 21.59 | |
| 13G | BlackRock Inc. | 6.90 | 355.38 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 284,689 | 1,099,250 | 25.90 | |
| 113,509 | 746,049 | 15.21 | |
| 146,180 | 825,218 | 17.71 | |
| 113,379 | 893,453 | 12.69 | |
| 104,270 | 928,657 | 11.23 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SNDX – Syndax Pharmaceuticals, Inc. | SPRO – Spero Therapeutics, Inc. |
| SRPT – Sarepta Therapeutics, Inc. | STOK – Stoke Therapeutics, Inc. |
| STTK – Shattuck Labs, Inc. |
Financial data and stock pages provided by
Fintel.io